No actionable signal. The $629K in insider sales is immaterial for a $111B market cap company. Both insiders sold on the same day, likely due to a planned 10b5-1 or blackout window opening. No bearish read-through to the stock. Monitor next 8-K or earnings for pipeline updates on Vertex's cystic fibrosis and pain programs.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 20 $430.05entry
- T+1 · 6mo ago +0.77%α +0.58% · $433.38
- T+5 · 6mo ago +4.10%α +2.30% · $447.70
- T+20 · 5mo ago +6.73%α +6.77% · $458.99
- T+60 · 3mo ago +17.60%α +12.87% · $505.75
Price Chart
How similar events traded
Executive Summary
Two EVP-level insiders at Vertex (CMO and Chief Scientific Officer) sold open-market shares on the same day for a combined $629K. While this is a cluster of C-suite sales, the dollar amount represents only ~0.0006% of the company's $111B market cap, well below any material threshold. The sales occurred on the same date, which is consistent with a blackout-window opening or routine 10b5-1 plan execution rather than coordinated bearish sentiment.
Key Financial Metrics
Key Facts
- CMO Carmen Bozic sold 1,354 shares for $614K on May 15, 2026 at $453.45
- CSO Mark Bunnage sold 33 shares for $15K on May 15, 2026 at $453.45
- Combined sales of $629K represent ~0.0006% of $110.8B market cap
- Both sales occurred on the same day, suggesting common timing trigger (blackout window or 10b5-1 plan)
- Vertex has 82% analyst buy rating and $110.8B market cap
Financial Impact
Insider sales of $629K total, negligible relative to $110.8B market cap
Risk Factors
- Insider sales are routine for large-cap biopharma and not predictive here
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-VRTX-1779221136715 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers